Provided By PR Newswire
Last update: Apr 17, 2025
LA JOLLA, Calif., April 17, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation at Digestive Disease Week (DDW) 2025 being held May 3-6 in San Diego, CA, and the participation of Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, in both an oral presentation and a panel discussion at the American Society of Nephrology (ASN) 3rd Acute Kidney Injury: From Bench to Bedside Conference being held May 4-7 in Leesburg, VA.
Read more at prnewswire.comNASDAQ:CALC (11/13/2025, 8:21:20 PM)
3.23
-0.11 (-3.29%)
Find more stocks in the Stock Screener


